Begnini K R, Buss J H, Collares T, Seixas F K
Programa de Pós Graduação em Biotecnologia (PPGB), Grupo de Pesquisa em Oncologia Celular e Molecular, Biotecnologia/Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Campus Universitário s/n, Pelotas, 96010-900, RS, Brazil.
Appl Microbiol Biotechnol. 2015 May;99(9):3741-54. doi: 10.1007/s00253-015-6495-3. Epub 2015 Mar 21.
In the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Guérin (BCG) has been used for treating bladder cancer and it still remains at the forefront of immunotherapy for cancer patients. Although BCG-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50 % of patients. Since that BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. Herein, we discuss current advances in recombinant BCG construction, research, concerns, and future directions to promote the development of this promising immunotherapeutic approach for bladder cancer.
在过去三十年中，膀胱内灌注卡介苗（BCG）已被用于治疗膀胱癌，并且它仍然处于癌症患者免疫治疗的前沿。尽管基于卡介苗的疗法是针对这类肿瘤最有效的膀胱内治疗方法，也是已知唯一能减少进展为肌层浸润性膀胱癌的药物，但卡介苗在大约30%-40%的病例中无效，高达50%的患者会出现疾病复发。由于卡介苗因其独特特性被认为是一种有效的抗原递送载体，对这些分枝杆菌进行基因操作在寻找毒性更低、效力更强的膀胱癌免疫治疗药物方面具有吸引力。在此，我们讨论重组卡介苗构建、研究、关注点及未来方向的当前进展，以促进这种有前景的膀胱癌免疫治疗方法的发展。
